* other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s). * receipt of medications intended to prevent covid-19. * previous microbiological diagnosis of covid-19. * previous covid-19 vaccination other than comirnaty (pfizer) * individuals at high risk for severe covid-19 (e.g. bmi \> 40, diabetes, heart- end/or lung disease), who are planned to receive covid vaccine within the next two months. * immunosuppressed individuals with known or suspected immunodeficiency, as determined by history. * individuals with an active autoimmune disease requiring therapeutic intervention. * receipt of systemic or topical corticosteroids. * bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * women who are pregnant or breastfeeding. * planned pregnancy within four weeks after injection. * positive serological test for sars-cov-2 anti-n igm and/or igg antibodies at screening visit. * sars-cov-2 pcr-positive mid-turbinate/throat swab at the screening before receipt of the vaccine dose. * participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. * receipt of any other non-study vaccine within 28 days, before receipt of the study dose. * anticipated receipt of any other non-study vaccine within 28 days, after the study dose administration.

* other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s). * receipt of medications intended to prevent covid-19. * previous microbiological diagnosis of covid-19. * previous covid-19 vaccination other than comirnaty (pfizer) * individuals at high risk for severe covid-19 (e.g. bmi \> 40, diabetes, heart- end/or lung disease), who are planned to receive covid vaccine within the next two months. * immunosuppressed individuals with known or suspected immunodeficiency, as determined by history. * individuals with an active autoimmune disease requiring therapeutic intervention. * receipt of systemic or topical corticosteroids. * bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. * women who are pregnant or breastfeeding. * planned pregnancy within four weeks after injection. * positive serological test for sars-cov-2 anti-n igm and/or igg antibodies at screening visit. * sars-cov-2 pcr-positive mid-turbinate/throat swab at the screening before receipt of the vaccine dose. * participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. * receipt of any other non-study vaccine within 28 days, before receipt of the study dose. * anticipated receipt of any other non-study vaccine within 28 days, after the study dose administration.

other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s). receipt of medications intended to prevent covid-19. previous microbiological diagnosis of covid-19. previous covid-19 vaccination other than comirnaty (pfizer) individuals at high risk for severe covid-19 (e.g. bmi > 40, diabetes, heart- end/or lung disease), who are planned to receive covid vaccine within the next two months. immunosuppressed individuals with known or suspected immunodeficiency, as determined by history. individuals with an active autoimmune disease requiring therapeutic intervention. receipt of systemic or topical corticosteroids. bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. women who are pregnant or breastfeeding. planned pregnancy within four weeks after injection. positive serological test for sars-cov-2 anti-n igm and/or igg antibodies at screening visit. sars-cov-2 pcr-positive mid-turbinate/throat swab at the screening before receipt of the vaccine dose. participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. receipt of any other non-study vaccine within 28 days, before receipt of the study dose. anticipated receipt of any other non-study vaccine within 28 days, after the study dose administration.

other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s). receipt of medications intended to prevent covid-19. previous microbiological diagnosis of covid-19. previous covid-19 vaccination other than comirnaty (pfizer) individuals at high risk for severe covid-19 (e.g. bmi > 40, diabetes, heart- end/or lung disease), who are planned to receive covid vaccine within the next two months. immunosuppressed individuals with known or suspected immunodeficiency, as determined by history. individuals with an active autoimmune disease requiring therapeutic intervention. receipt of systemic or topical corticosteroids. bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. women who are pregnant or breastfeeding. planned pregnancy within four weeks after injection. positive serological test for sars-cov-2 anti-n igm and/or igg antibodies at screening visit. sars-cov-2 pcr-positive mid-turbinate/throat swab at the screening before receipt of the vaccine dose. participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. receipt of any other non-study vaccine within 28 days, before receipt of the study dose. anticipated receipt of any other non-study vaccine within 28 days, after the study dose administration.